The global nature of the Healthineers was highlighted in August, when reports surfaced that it was looking to ease tariff hits to costs by altering supply routes to ship more of its U.S.-destined goods from European factories rather than Chinese ones, according to comments by chief financial officer Jochen Schmitz.

“This won’t happen without leaving some trace on our results because we have to change logistic chains ... depending on how the situation develops,” he said, following the company's conference call on Q3 results.


He advised the tariff impact would be low – “a low single digit million euro impact on Healthineers’ results this year,” said the wire service.

“When it stays in this range it won’t be a catastrophe but of course the topic is very, very regrettable because it significantly impairs global trade,” he said.

As of 2017, Healthineers had 23 U.S. plants and sites, with another 17 in Europe, the Middle East and Africa, and the Asia-Pacific region housing 11.

Siemens Healthineers shares surged after its Frankfurt Stock Exchange IPO in March. Buyers snapped up 150 million shares, representing 15 percent of Healthineers. Siemens stated that it intended to continue as a majority shareholder for the long haul, according to reports at the time.

The IPO had been a long time coming, with news of the intention to list Healthineers first breaking in November, 2016.

Back to HCB News

Business Affairs Homepage